OC
GMAB icon

Oppenheimer & Co’s Genmab GMAB Stock Holding History

Oppenheimer & Co’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,857
Closed -$521K – 1532
2021
Q1 		$521K Sell
15,857
-12,664
-44% -$476K 0.01% 947
2020
Q4 		$1.16M Buy
28,521
+10,469
+58% +$391K 0.02% 598
2020
Q3 		$661K Buy
+18,052
New +$653K 0.02% 718

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Oppenheimer & Co's GMAB Position: Q2 2021 in Review

Oppenheimer & Co sold out of Genmab (GMAB) in Q2 2021, closing a stake of 15,857 shares — an estimated $521K sold.

Oppenheimer & Co first reported a position in GMAB in Q3 2020 and held it in 3 quarters. The position peaked at $1.16M in Q4 2020. 212 funds tracked by Wall St. Rank hold GMAB as of Q2 2021.

  • Oppenheimer & Co reported no remaining Genmab position as of Q2 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 15,857 Genmab shares in Q2 2021, an estimated $521K.
  • Oppenheimer & Co first reported a position in Genmab in Q3 2020 and held it in 3 quarters.
  • Oppenheimer & Co's Genmab position peaked at $1.16M in Q4 2020.
  • 212 funds tracked by Wall St. Rank held Genmab as of Q2 2021.

Based on Oppenheimer & Co's 13F filing for Q2 2021, filed 3 Aug 2021.